



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

41st Annual Meeting of the Italian Association for the Study of the Liver (A.I.S.F.) (Aula Magna, Università degli Studi di Roma "La Sapienza") Roma, February 21-22, 2008

Thursday, February 21

- | | | | |
|-------------|--|-------------|--|
| 08.30-10.00 | Oral Communications
<i>Chairpersons:</i> F.B. Bianchi, <i>Bologna</i>
S. Fagioli, <i>Bergamo</i> | 11.30-13.00 | Oral Communications
<i>Chairpersons:</i> N. Caporaso, <i>Napoli</i>
G. Svegliati Baroni, <i>Ancona</i> |
| 08.30-08.45 | HCV and ethanol induce mitosis dysregulation via different intracellular pathways
Alisi, M. Ghidinelli, A. Spaziani, C. Balsano, <i>Rome, L'Aquila</i> | 11.30-11.45 | GP120 induces directional migration of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis
S. Galastri, R. Bruno, P. Sacchi, S. Cima, A. Caligiuri, M. Pinzani, F. Marra, <i>Florence, Pavia</i> |
| 08.45-09.00 | Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome
G. Tarantino, V. Di Marco, P.L. Almasio, F. Barbaria, A. Ciaccio, F. D'Antoni, R. Di Stefano, A. Iacò, A. Licata, S. Petta, A. Craxì, <i>Palermo</i> | 11.45-12.00 | Characterization of snail1 transcription factor in experimental liver fibrosis and in the activation process of hepatic stellate cells
M. Scarpa, A. Grillo, P. Brun, G. Palù, I. Castagliuolo, D. Martines, <i>Padua</i> |
| 09.00-09.15 | Correlates and predictive value of early HCV-RNA kinetic during antiviral treatment
E. Durante-Mangoni, R. Zampino, C. Caianiello, D. Pinto, R. Utili, G. Ruggiero, <i>Naples</i> | 12.00-12.15 | Normal ALT should not preclude liver biopsy in patients with NAFLD
A.L. Fracanzani, L. Valenti, E. Bugianesi, G. Marchesini, M. Andreoletti, A. Colli, C. Bertelli, E. Fatta, S. Fargion, <i>Milan, Turin, Bologna, Lecco</i> |
| 09.15-09.30 | Genotype dependent pattern of PegInterferon ALFA-2B/ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis: a single center study of 471 naïve patients
A. Aghemo, M.G. Rumi, S. Monico, G.M. Prati, G. Ronchi, M. Colombo, <i>Milan</i> | 12.15-12.30 | Transient elastography separates inactive HBV carriers from HBEAG minus disease
S. Maimone, V. Calvaruso, M. Pleguezuelo, G. Amaddeo, G. Squadrito, G. Raimondo, G.M. Dusheiko, <i>London, Messina</i> |
| 09.30-09.45 | Results of Randomized Controlled Trial on the Impact of prolonged combination anti HCV treatment on relapse rate in HIV/HCV coinfecting patients with HCVRNA negativization at the end of a 24-48 weeks course of treatment: The ROMANCE study
M. Puoti, B. Zanini, A. De Luca, G.P. Quinzan, R. Allegri, R. Bruno, A. Orani, T. Quirino, T. Santantonio, G. Pastore, G. Cristini, F. Suter, R. Cauda, G. Carosi, ROMANCE-MASTER study group | 12.30-12.45 | Liver Fibrosis in Adult Thalassemia Patients Assessed by Transient Elastography
M. Fraquelli, E. Cassinerio, E. Volpato, C. Rigamonti, M.D. Cappellini, D. Conte, M. Colombo, <i>Milan</i> |
| 09.45-10.00 | The SAFE (sequential algorithm for fibrosis evaluation) biopsy: a new approach to stage fibrosis in chronic hepatitis C
G. Sebastiani, P. Halfon, L. Castera, S. Pol, D. L. Thomas, A. Mangia, V. Di Marco, M. Pirisi, M. Voiculescu, M. Bourliere, A. Alberti, <i>Padua, Marseille, Bordeaux, Paris, Baltimore, San Giovanni Rotondo, Palermo, Novara, Bucharest, Romania</i> | 12.45-13.00 | PHES standardization in Italy and its comparison to EEG findings
F. Campagna, S. Olanas, D. Mapelli, P. Iannizzi, M. Penzo, P. Angeli, A. Gatta, P. Amodio, <i>Padua</i> |
| 10.00-10.30 | Break and Posters view
<i>Tutors:</i> S. Bellentani, <i>Modena</i>
D. Conte, <i>Milano</i> | 13.00-14.00 | Lunch and Posters view
<i>Tutors:</i> F. Marra, <i>Firenze</i>
M. Persico, <i>Napoli</i> |
| 10.30-11.30 | General Assembly II | 14.00-15.00 | General Assembly III:
Report of A.I.S.F. Scientific Commissions and Study Groups
<i>Chairpersons:</i> A.I.S.F. Coordinating Committee |
| | | 15.00-16.15 | Joint Symposium A.I.S.F.-S.I.U.M.B.
"Portal Thrombosis"
<i>Chairpersons:</i> R. de Franchis, <i>Milano</i>
C. Filice, <i>Pavia</i> |
| | | 15.00-15.15 | Clinical aspects - M. Pompili, <i>Roma</i> |
| | | 15.15-15.30 | Focus on II nd level diagnosis - P. Ricci, <i>Roma</i> |
| | | 15.30-15.45 | Treatment and prophylaxis - P. Angeli, <i>Padova</i> |
| | | 15.45-16.00 | Surgical aspects - A.D. Pinna, <i>Bologna</i> |
| | | 16.00-16.15 | Questions and answers |



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- 16.15-16.45 **Break and Posters view**
Tutors: S. Bellentani, Modena
D. Conte, Milano
- 16.45-17.15 **2006 A.I.S.F. Fellowships Report**
Chairperson: A. Pietrangelo, Modena
- Effect of calcineurin inhibitors on AT1 and AT2 angiotensin receptor of human hepatic cells and its intracellular signaling**
S. Grazioli, Novara
- The chemokine receptor CXCR3 as a modulator of endothelial cell biology and liver injury**
I. Petrai, Firenze
- Retinol-binding Protein 4: A New Marker of Virus-Induced Steatosis in Patients Infected with HCV Genotype 1**
S. Petta, Palermo
- 17.15-18.45 **Oral Communications**
Chairpersons: A. Benedetti, Ancona
P. Lampertico, Milano
- 17.15-17.30 **Redox - sensitive GSK-3b inhibition and late vegf release mediate hypoxia-dependent epithelial - mesenchymal transition and increased invasiveness in human HepG2 cells**
S. Cannito, E. Novo, A. Compagnone, L. Valfrè di Bonzo, C. Busletta, E. Zamara, A. Bandino, C. Cravanzola, V. Bravoco, S. Colombatto, Maurizio Parola, Turin
- 17.30-17.45 **GAS6 is produced by human stellate cells and its plasma levels reflect the severity of cirrhosis**
C. Marconi, R. Minisini, P. Sainaghi, C. Fabris, L. Franzosi, E. Mossio, F. Alciato, P. Toniutto, C. Smirne, G. Avanzi, M. Pirisi, Novara, Udine
- 17.45-18.00 **First evidence that albumin can directly improve cardiac contractility in cirrhotic rats**
G. Ceolotto, I. Papparella, M. Cavalli, A. Sticca, L. Franco, S. Bova, A. Semplicini, A. Gatta, P. Angeli, Padua
- 18.00-18.15 **Increase of left ventricular ejection fraction in advanced cirrhosis: an attempt to compensate for central hypovolemia?**
M. Cazzaniga, G. Pagnozzi, S. Baronchelli, G. Gobbo, C. Coman, V. Montericcio, F. Salerno, Milano
- 18.15-18.30 **Transjugular intrahepatic portosystemic shunt (TIPS) is feasible in non cirrhotic patients with cavernomatous transformation of the portal vein**
C. Marzano, S. Angeloni, F.M. Salvatori, P. Rossi, A. De Santis, M. Merli, A.F. Attili, O. Riggio, Rome
- 18.30-18.45 **Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: preliminary results of the "A.I.S.F.-Epasco" study**
S. Bruno, P. Almasio, S. Saibeni, C. Vandelli, A. Ascione, M. Felder, M. Tommasini, P. Andreone, G.B. Gaeta, A. Andriulli, C. Furlan, F. Salerno, C. Loguercio, M. Persico, T. Stroffolini, A.I.S.F.-EPASCO Collaborative Study Group

Friday, February 22

- 08.30-10.00 **Oral Communications**
Chairpersons: F. Farinati, Padova
F. Trevisani, Bologna
- 08.30-08.45 **Evidence for epithelial-mesenchymal transition in the biliary epithelium of human cholangiocarcinoma**
L. Fabris, M. Cadamuro, C. Spirlì, R. Fiorotto, A. Sonzogni, M. Colledan, S. Fagioli, L. Okolicsanyi, M. Strazzabosco, Bergamo, Padua, New Haven (USA)
- 08.45-09.00 **MiR-221 regulates p27/kip1 in hepatocellular carcinoma**
F. Fornari, L. Gramantieri, M. Ferracin, S. Sabbioni, A. Veronese, C. Giovannini, M. Galassi, G.L. Grazi, M. Negrini, L. Bolondi, Bologna, Ferrara
- 09.00-09.15 **Leptin enhances the growth of cholangiocarcinoma in vivo: an experimental study**
G. Fava, G. Alpini, G. Svegliati-Baroni, C. Rychlicki, S. Saccomanno, L. Trozzi, C. Candelaresi, A. Di Sario, M. Marzioni, A. Benedetti, Ancona, Temple (USA)
- 09.15-09.30 **Differential VEGF-A protein expression between small HCC and cirrhosis at distance from the tumor correlates with serum VEGF-A and alpha-fetoprotein**
S. Ginanni Corradini, S. Morini, F. Liguori, S. Carotti, A. Onetti Muda, M.A. Burza, M. Siciliano, A. Molinaro, A. Cantafora, I. Blotta, M. Merli, P. Berloco, M. Rossi, A.F. Attili, E. Gaudio, Rome
- 09.30-09.45 **Molecular staging of HCC patients eligible for potentially radical therapies**
A. Vitale, U. Cillo, G. Ometto, F. D'Amico, E. Gringeri, M. Valmasoni, A. Brolese, G. Zanùs, D. Neri, P. Boccagni, A. Carraro, P. Violi, A. Pauletto, F. Farinati, P. Burra, D.F. D'Amico, Padua
- 09.45-10.00 **Surgical resection versus laparoscopic radiofrequency ablation for treatment of hepatocellular carcinoma < 5 cm in child a patients**
R. Santambrogio, A. Pisani Ceretti, M. Barabino, M. Costa, E. Opocher, Milan
- 10.00-12.20 **Special Workshop "Emerging Pharmacological Therapies for HCC"**
Chairpersons: U. Cillo, Padova
G. Raimondo, Messina
- 10.00-10.20 **Molecular pathogenesis of HCC: viruses, candidate genes and contro circuit**
M. Levrero, Roma
- 10.20-10.40 **HCC 2008: prognosis prediction, staging and current treatment options**
M. Colombo, Milano
- 10.40-11.00 **Targeted therapies in the treatment of cancer**
B. Daniele, Benevento
- 11.00-11.10 **Questions and answers**
Chairpersons: F. Bonino, Milano
V. Mazzaferro, Milano



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- 11.10-11.30 **Molecular targeted therapies in HCC: The sorafenib case**
J.M. Llovet, *Barcelona, New York*
- 11.30-11.50 **Future strategies and end points in clinical trials for the advanced and intermediate stage HCC**
L. Bolondi, *Bologna*
- 11.50-12.10 **Crucial role of a multidisciplinary approach in HCC treatment**
A. Craxì, *Palermo*
- 12.10-12.20 **Questions and answers**
- 12.20-13.20 **General Assembly IV**
- 13.20-14.15 **Lunch and Posters view**
Tutors: F. Marra, Firenze
M. Persico, *Napoli*
- 14.15-15.45 **Oral Communications**
Chairpersons: P. Burra, Padova
D. Prati, *Lecco*
- 14.15-14.30 **Bone marrow-derived liver-committed stem cells give rise to combined hepatocholangiocarcinomas in rats**
A.C. Piscaglia, T.D. Shupe, M.L. Novi, M.C. Campanale, B.E. Petersen, A. Gasbarrini, *Rome, Gainesville (USA)*
- 14.30-14.45 **Characterization of mesenchymal stem cells-like in human liver**
R. Ratti, N. Saulnier, F. Colombo, L. Porretti, A. Cattaneo, M.A. Puglisi, G. Rossi, G. Piccolo, B. Foglieni, D. Prati, *Milan, Rome, Lecco*
- 14.45-15.00 **Hyperbaric oxygen reduces rat liver preservation injury preserved in a hypothermic machine perfusion**
F. Giannone, P. Caraceni, G. Sgarbi, A. Baracca, G. Solaini, M. Domenicali, I. Grattagliano, G. Lenaz, D. Trerè, M. Bernardi, *Bologna*
- 15.00-15.15 **Prospective study of NK cell phenotype in recurrent HCV infection after liver transplant**
S. Varchetta, B. Oliviero, F. Donato, F. Agnelli, G. Rossi, C. Rigamonti, M. Colombo, D. Mavilio, M.U. Mondelli, *Pavia, Milan, Bethesda (USA)*
- 15.15-15.30 **G-CSF administration is not related to Peg-IFN Alfa-2B treatment duration nor response in liver transplanted patients with HCV recurrence**
F. Lodato, M.R. Tamè, M. Di Girolamo, F. Azzaroli, A. Gramenzi, S. Berardi, P. Andreone, A.D. Pinna, E. Roda, G. Mazzella, *Bologna*
- 15.30-15.45 **Pharmacokinetics, efficacy and safety of intramuscular and intravenous of hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation**
A. Marzano, P. Andreone, R. Volpes, D. Canova, C. Cursaro, A. Riilli, B. Fiorentino, M. Bacci, S. Guazzini, P. Burra, *Padua, Bologna, Turin*
- 15.45-16.00 **Presentation of the best Italian paper in 2006**
Chairpersons: A. Francavilla, Bari
A. Gatta, *Padova*
- AISF/FADE prize for the best clinical paper**
"The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients"
A. Sangiovanni, GM Prati, P Fasani, G. Ronchi, R Romeo, M Manini, E Del Ninno, A Morabito, M Colombo
Hepatology 2006;43(6):1303-10
Presenter: M. Bernardi, Bologna
- AISF prize for the best basic paper**
"Liver Microsomal Triglyceride Transfer Protein Is Involved in Hepatitis C Liver Steatosis"
S Mirandola, S Realdon, J Iqbal, M Gerotto, F Dal Pero, G Bortoletto, M Marcolongo, A Vario, C Datz, MM Hussain, A Alberti
Gastroenterology 2006;130(6):1661-69
Presenter: D. Alvaro, Roma
- 16.00-16.15 **Presentation of the A.I.S.F. distinguished service award to Prof. Federico Manenti**
Presenter: A. Gasbarrini, Roma
- 16.15-17.30 **Oral Communications**
Chairpersons: M. Koch, Roma
T. Pollicino, *Messina*
- 16.15-16.30 **Clinical and virological survey of HBSAG positive patients in a single italian region**
F. Torre, M. Basso, A. Picciotto, *Genoa (on behalf of The Ligurian HBV Group)*
- 16.30-16.45 **The control of HBV replication that leads to HBeAg loss does not prevent the emergence of pre-core defective variants in genotype d infected children**
P. Colombatto, C. Barbera, F. Bortolotti, A. Maina, F. Moriconi, G. Calvo, M. Baldi, F. Oliveri, F. Bonino, M.R. Brunetto, *Pisa, Turin, Milan, Padua*
- 16.45 -17.00 **Chronic hepatitis B vaccine therapy: hepatitis B vaccination combined with hepatitis B immunoglobulins and lamivudine**
I. Lenci, P. Piccolo, D. Di Paolo, C. Cerocchi, M. Trinito, M. Angelico, *Rome*
- 17.00-17.15 **"De novo" combination with adefovir and lamivudine is more effective than adefovir "add on" and as effective as lamivudine monotherapy in antiviral treatment of chronic HBV infection**
M. Puoti, F. Zacchi, S. Zaltron, A. Spinetti, S. Rossi, K. Prestini, M. Mendeni, L. Biasi, G. Carosi, *Brescia*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

- 17.15-17.30 **Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of hbeag-negative chronic hepatitis B (CHB)** M. Rizzetto, P. Marcellin, P. Andreone, M. Buti, Z. Krastev, G. Germanidis, K. Kaita, I. Kotzev, P. Buggisch, F. Weillert, J. Sorbel, J. Anderson, E. Mondou, F. Rousseau, *Turin, Clichy (France), Bologna, Barcelona (Spain), Sofia (Bulgary), Thessaloniki (Greece), Winnipeg (Canada), Varna (Bulgary), Hamburg (Germany), Hamilton (New Zealand), USA*
- 17.30-17.45 **The course of chronic infection with hepatitis Delta virus: a 20-year cohort study of 299 Italian patients**
R. Romeo, A. Sangiovanni, M.G. Rumi, A. Russo, E. Del Ninno, G. Ronchi, M. Colombo, *Milan*
- 17.45-18.00 **Young Investigators Awards**
Presenters for the 2 best oral communications
Basic: A.L. Zignego, *Firenze*
Clinical: C. Puoti, *Marino*
Presenters for the 2 best posters
Basic: F. Marra, *Firenze* - M. Persico, *Napoli*
Clinical: S. Bellentani, *Modena* - D. Conte, *Milano*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

POSTER SESSION

1 Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of HBeAg-positive chronic hepatitis B (CHB)

P. Andreone, J. Heathcote, M. Rizzetto, E. Gane, R. DeMan, S. Lee, R. Flisiak, J. Sorbel, J. Anderson, E. Mondou, F. Rousseau, *Bologna, Toronto (Canada), Turin, Auckland (New Zealand), Rotterdam (The Netherlands), Calgary (Canada), Bialystok (Poland), USA*

2 A prospective study comparing two algorithms that combine non-invasive methods for liver fibrosis in chronic hepatitis C

L. Castera, G. Sebastiani, B. Le Bail, V. de Ledinghen, P. Couzigou, A. Alberti, *Bordeaux (France), Padua*

3 Older age is associated with an impaired response to combination pegylated interferon and ribavirin treatment for chronic hepatitis C

E. Minola, M. Puoti, M.L. Sorlini, G. Antonini, O. Fracassetti, C. Baiguera, V. Ravasio, D. Manno, M. Airoidi, M. Mendeni, L. Biasi, F. Suter, G. Carosi, *Brescia, Bergamo*

4 Transient elastography vs. platelets or APRI score to assess fibrosis in chronic hepatitis C

V. Calvaruso, C. Cammà, F. Bronte, S. Maimone, G. Alaimo, V. Di Marco, G. Dusheiko, A.K. Burroughs, A. Craxi, *Palermo, London*

5 HCV Genotype 2 and 3 respond differently to anti HCV treatment

M. Puoti, E. Minola, M.L. Sorlini, G. Antonini, C. Baiguera, D. Manno, O. Fracassetti, V. Ravasio, M. Airoidi, K. Prestini, G.P. Quinzan, L. Biasi, F. Suter, G. Carosi, *Brescia, Bergamo*

6 Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients

A. Sangiovanni, M.A. Manini, M. Iavarone, M. Fraquelli, L. Forzenigo, R. Romeo, G. Ronchi, M. Colombo, *Milan*

7 Exendin-4 protects cholangiocytes from apoptosis, both in vitro and in vivo

M. Marziani, G. Alpini, S. Saccomanno, G. Fava, C. Candelaresi, C. Rychlicki, H. Francis, L. Trozzi, J. Venter, A. Benedetti, *Ancona, Temple (USA)*

8 Extrinsic and intrinsic apoptosis pathways in chronic liver diseases

A. Kotsafti, C. Carlotto, R. Cardin, F. Farinati, M. Bortolami, *Padua*

9 Incidence of late HCC recurrence after resection remains higher than first HCC: implications for patients management

A. Cucchetti, F. Piscaglia, L. Benvegnù, E. Caturelli, A. Gianstefani, G.L. Grazi, L. Bolondi, A.D. Pinna, *Bologna, Padua, Viterbo*

10 Efficacy and safety of treatment with pegylated interferon and ribavirin for hepatitis C virus-associated cryoglobulinemia: a multicenter study

C. Mazzaro, A.M. Baragiotta, G. Pozzato, G. Monti, D. Filippini, C. Donada, A. Tellan, A. Gabrielli, S. De Vita, GISC (GISC Gruppo Italiano Studio Crioglobulinemia), *Pordenone, Trieste, Saronno, Milan, Ancona, Udine*

11 Older donor age is associated with increased donor oxidative stress and failure to restore basal total protein graft content after ischemia reperfusion injury in human liver transplantation

S. Ginanni Corradini, A. Molinaro, M. Siciliano, E. Costi, R. Monticolo, C. Pirazzi, M.A. Burza, M. Merli, A.F. Attili, G.L. Mennini, P. Berloco, M. Rossi, L. Iuliano, *Rome*

12 Efficacy of AISF guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice

S. Angeloni, C. Leboffe, A. Parente, M. Venditti, A. Giordano, M. Merli, O. Riggio, *Rome*

13 Notch3 down-regulation increases the sensitivity of HepG2 liver cells to doxorubicin

C. Giovannini, K. B. Marcu, L. Gramantieri, P. Chieco, F. Lago, S. Pianetti, E. Ramazzotti, L. Bolondi, *Bologna, New York*

14 Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination: a 4- year cohort study in 63 patients

P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, M. Colombo, *Milan*

15 Increased NK cell lytic activity in chronic HCV infection

B. Oliviero, S. Varchetta, A. Cerino, G. Michelone, M. Zaramella, D. Mavilio, M.U. Mondelli, *Pavia, Bethesda (USA)*

16 Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing Allo-SCT

L. Mezzabotta, L. Giaccone, I. Resta, A. Marengo, F. Fiore, R. Sorasio, M. Festuccia, M. Boccadoro, B. Bruno, M. Rizzetto, A. Marzano, *Turin*

17 Ape1/Ref-1 mRNA level in Human Hepatocellular Carcinoma is higher in HCV related cancers

V. Di Maso, L.S. Crocè, U. Baccarani, F. Lupo, C. Avellini, G. Tell, C. Tiribelli, *Trieste, Udine, Turin*

18 In vitro evaluation of hepatic transdifferentiation of adipose- and bone marrow-derived stromal cells

N. Saulnier, M.A. Puglisi, M. Barba, M.L. Novi, A.C. Piscaglia, M.A. Zocco, F. Fiore, S. Alfieri, G. Leone, G.B. Doglietto, G. Gasbarrini, A. Gasbarrini, *Rome*

19 JAK2 (V617F) mutation levels in patients affected by Budd-Chiari syndrome and non-cirrhotic extra-hepatic portal vein obstruction

C. Marzano, A. Rago, S. Angeloni, A. Fama, C. Laganà, A. Tafuri, O. Riggio, *Rome, Reggio Calabria*

20 Retinol-binding protein 4 (RBP4): a new marker of g1 HCV-induced steatosis

S. Petta, C. Cammà, V. Di Marco, F. Barbaria, D. Cabibi, R. Caldarella, S. Ciminnisi, A. Licata, F. Massenti, A. Mazzola, G. Tarantino, G. Marchesini, A. Craxi, *Palermo, Bologna*

21 Safety and efficacy profile of the antiviral therapy of HCV chronic hepatitis in elderly patients

M. Rendina, A. Pastorelli, F. Losito, P. Paziienza, A. Bucci, R. Bringiotti, A. Francavilla, *Bari*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

22 Risk factors of aminotransferase elevation in a population of virus-free blood donors. A multicentre italian study

F. Morisco, A. Mele, G. Taliani, A. Smedile, S. Caronna, G. Niro, M. Levrero, M.T. Fiorillo, M.E. Tosti, T. Stroffolini, N. Caporaso, *Naples, Rome, Turin, San Giovanni Rotondo, Reggio Calabria*

23 Liver transplantation (LT) for alcoholic liver disease in adults in Europe

M. Senzolo, P. Burra, R. Adam, V. Karam, G. Germani, J. Nueberger, for ELITA and of behalf of ELTR liver transplant centers, *Padua, Paris, Birmingham*

24 The endocannabinoid system is up-regulated in primary biliary cirrhosis

R. Lazzari, N. Candeo, V. Macchi, A. Variola, M. Guido, D. Colavito, A. Leon, N.V. Bergasa, A. Floreani, *Padua, New York*

25 Hepatocellular carcinoma induces specific igm-biomarkers immune complexes

L. Beneduce, G. Pesce, A. Gallotta, F. Zampieri, A. Biasolo, N. Tono, P. Pontisso, G. Fassina, *Venice, Padua*

26 Acute gastrointestinal bleeding prolongs QT interval in cirrhosis

A. Zambruni, A. Di Micoli, E. Bracci, K. Fontana, P. Caraceni, M. Domenicali, F. Mirici-Cappa, V. Santi, G. Magini, R. Casadio, M. Frigerio, M. Bernardi, F. Trevisani, *Bologna*

27 AMP-activated protein kinase (AMPK) regulates the activation process of hepatic stellate cells

C. Bertolani, A. Caligiuri, F. Vizzutti, C. Tosti Guerra, M. Pinzani, F. Marra, *Florence*

28 High prevalence of metabolic syndrome after liver transplantation does not influence long-term survival

S. Francioso, F. Angelico, G. Tisone, L. Baiocchi, I. Lenci, L. Tariciotti, M. Angelico, *Rome*

29 Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B

M. Fasano, M. Heichen, A. Guastadisegni, S. Palattella, G. Pastore, T. Santantonio, *Bari*

30 Incidence and timing of infections in liver transplanted patients in Italy

P. Piselli, M. Scuderi, C. Zanfi, A. Lauro, S. Ferretti, R. Santoro, S. Barzoni Secchia, M. Gabriel Arana, C. Cimaglia, G. Ferretti, N. Gusman, P.B. Berloco, G.M. Ettore, G. Vennarecci, A. Pinna, P. Grossi, A. Nanni Costa, D. Serraino, N. Petrosillo, E. Girardi, E. Puro, G. Ippolito, *Rome, Bologna, Varese, Aviano*

31 Percutaneous radio-frequency ablation of small HCC: factors related to clinical outcome and recurrence of disease.

F. Piscaglia, N. Celli, M.A. Zocco, M. Mancini, E. Sgrini, A. Gianstefani, A. Bazzocchi, S. Costantini, R. Righini, L. Bolondi, *Bologna*

32 "Prophylactic" Adefovir "add on" is associated with a lower rate of virologic breakthrough in patients with optimal response to lamivudine and undetectable HBVDNA

M. Puoti, F. Zacchi, S. Zaltron, A. Spinetti, S. Rossi, K. Prestini, M. Mendeni L. Biasi, G. Carosi, *Brescia*

33 Fibrosis progression on protocol liver biopsies in patients with HCV recurrence following liver transplantation (LT)

E. De Martin, M. Senzolo, S. Boninsegna, M. Guido, S.M. Gambato, G. Germani, A. Masier, F.P. Russo, G. Zanusi, U. Cillo, P. Burra, *Padua*

34 Transient elastography (TE) is more effective for the identification of HCV patients with severe ($\geq F3$) rather than significant ($\geq F2$) liver fibrosis

U. Arena, F. Vizzutti, J.G. Abraltes, G. Corti, C. Stasi, S. Moscarella, S. Milani, E. Loreface, A. Petrarca, G. Laffi, F. Marra, M. Pinzani, *Florence, Barcelona*

35 NASH is a peculiar pathological expression of insulin-resistance

G.P. Daniele, G. Di Palma, B. Palmentieri, R. Torella, T. Salvatore, M. Persico, *Naples*

36 Free fatty acid induce oxidative stress in HEPG2-cell. Protective role of anti-oxidant substances and adiponectin

G. Soardo, D. Donnini, C. Pagano, C. Milocco, L. Domenis, D. Cappello, D. De Silvestri, L.A. Sechi, *Udine, Padua*

37 Validation of the italian version of Fisk fatigue severity score (FFSS) and PBC-40

L. Montali, A. Frigerio, M. Miglioretti, M. Podda, C. Selmi, L. Vecchio, C. Cocchi, P. Riva, P. Invernizzi, *Milan*

38 Radiofrequency thermal ablation of hepatocellular carcinoma (HCC) can enhance NK cell response

A. Zerbini, M. Pilli, G. Pelosi, E. Negri, A. Molinari, D. Laccabue, S. Cerioni, F. Fagnoni, C. Ferrari, G. Missale, *Parma, Pavia*

39 Doppler perfusion index (DPI) and HOMA are highly predictive of fatty liver in patients with NAFLD

M. Dugoni, L. Miglioli, L. Borelli, R. Anderlini, G. Bedogni, M. Mariano, N. Battistini, S. Bellentani, *Modena, Reggio Emilia*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

(Associazione riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998)

1st A.I.S.F. POST-GRADUATE COURSE
“BASIC LIVER ULTRASONOGRAPHY”
(Best Western Hotel Globus - Viale Ippocrate 119 - Roma)

Course Directors: G.L. Rapaccini, Roma and G. Svegliati Baroni, Ancona

Saturday, February 23

SCIENTIFIC PROGRAMME

- 09.00-09.05 **The role of ultrasonography in the diagnosis of chronic liver disease**
G.L. Rapaccini, *Roma*
- 09.05-09.35 **Physics, technology and semantics**
S. Corradin, *Padova*
- 09.35-10.05 **US anatomy of normal liver and spleen**
V. Cantisani, *Roma*
- 10.05-10.35 **Chronic liver disease**
A. Colli, *Lecco*
- 10.35-11.05 **Portal hypertension**
D. Sacerdoti, *Padova*
- 11.05-11.35 **Discussion and break**
- 11.35-11.55 **Benign tumors**
M. Pompili, *Roma*
- 11.55-12.25 **Primary malignant tumors**
F. Piscaglia, *Bologna*
- 12.25-12.55 **Secondary malignant tumors**
F. Fornari, *Piacenza*
- 12.55-13.10 **The rational use of contrast agents in hepatic US**
F. Calliada, *Pavia*
- 13.10-13.30 **Discussion and conclusions**